United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: June 30, 2009
GeneLink, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | | | | |
| PA | | 00-30518 | | 23-2795613 |
| | | | | |
| (State or other | | (Commission File Number) | | (IRS Employer |
| Jurisdiction of | | | | Identification |
| Incorporation) | | | | No.) |
317 Wekiva Springs Road, #200, Longwood, FL 32779
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code:(800) 558-4363
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On June 30, 2009, the Board of Directors of GeneLink, Inc. appointed James Antal to the Board of Directors. Mr. Antal, 58, will serve as Chairman of the Audit Committee. Mr. Antal qualifies as an independent audit committee financial expert.
Mr. Antal is a member of the board of directors of Cleveland Biolabs, Inc. (Nasdaq:CBLI), a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications. He has served since 2006 and is presently chair of the Audit Committee and member of the Compensation Committee. Mr. Antal served as Chief Financial Officer of Experian Plc from 1996 to 2001 and as Chief Investment Officer of Experian from 2001 to 2002. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. He also served on the Board of Directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from The Ohio State University in 1973. He became a Certified Public Accountant (Ohio) in 1975. Starting in 2002, Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004, he joined the SIGA board of directors, and also currently serves on its audit and corporate governance committees. From May 2004 to August 2005, he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. In July 2005, he joined Pathway Data Inc, a privately held company engaged in consumer credit notification and identity theft assistance services, as its part-time Chief Financial Officer.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated July 6, 2009 of GeneLink, Inc.
- 2 -
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | | GeneLink, Inc.
(Registrant)
| |
| | By: | /s/ Monte E. Taylor, Jr. | |
| | | Monte E. Taylor, Jr. | |
| | | Chief Executive Officer | |
| |
Dated: July 6, 2009
- 3 -
EXHIBIT INDEX
| | | |
| Exhibit Number | | Description |
| 99.1 | | Press Release dated July 6, 2009 of GeneLink, Inc. |
